Detalles de la búsqueda
1.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739457
2.
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
Eur J Haematol
; 107(5): 573-582, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297437
3.
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
Haematologica
; 105(10): 2420-2431, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33054082
4.
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Haematologica
; 103(1): 80-90, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29025907
5.
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies.
Mycoses
; 61(9): 650-655, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693758
6.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol
; 92(10): 1037-1046, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28675513
7.
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Am J Hematol
; 91(8): 755-62, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27084986
8.
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Br J Haematol
; 186(6): e223-e225, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31348524
9.
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Br J Haematol
; 184(3): 457-460, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29359798
10.
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Ann Hematol
; 93(12): 2011-8, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24989345
11.
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.
Hematol Oncol
; 36(2): 498-499, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29052244
12.
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Ann Hematol
; 92(10): 1309-18, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23686116
13.
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
Am J Hematol
; 93(2): E33-E35, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29080220
14.
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.
Haematologica
; 102(9): e348-e351, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28495917
15.
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells.
Front Immunol
; 12: 753890, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34804039
16.
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
Leuk Lymphoma
; 61(1): 84-90, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31480933
17.
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.
Blood Adv
; 4(20): 5040-5049, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33075137
18.
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
Leuk Lymphoma
; 61(7): 1695-1701, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32186422
19.
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden.
Cancers (Basel)
; 13(1)2020 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33374216
20.
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.
Blood Cancer J
; 10(10): 96, 2020 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33024084